Health Care

Insider buying at AngioDynamics signals confidence, with execs boosting shares amid revenue growth and a bullish outlook for vascular tech.

Insightful look at Liquidia Corp’s largest insider sale: 3,596 shares off Stephen Bloch’s stake, market impact, and future biotech prospects.

Jasper Therapeutics COO’s $0.75 buy of 881 non‑voting convertible preferred shares shows top‑level confidence, hinting at future conversion and potential upside for investors.

Agwunobi John O’s routine sale of 392 Ensign Group (ENSG) shares at $171.06 shows a steady, non‑market‑reactive strategy, signaling long‑term confidence in the company’s health‑care trajectory.

Oncolytics CEO’s July 20 insider trades reveal a balanced strategy, selling shares while buying back at low prices amid FDA fast‑track approval for pelareorep in anal‑cancer patients, indicating long‑term confidence in the company’s oncolytic viroth…

Inside Abeona’s recent CFO sale: learn how insider trading, ZEVASKYN’s regulatory journey and cash‑burn worries shape investor confidence and what to watch next.

OKYO Pharma insider buying shows confidence in a pending Phase‑3 trial—what this means for investors and volatility.

Inside NewAmsterdam Pharma’s July 20 insider trades reveal a strategic buy‑low, sell‑high pattern that signals confidence, liquidity needs, and future growth in the cardiovascular space.

Insider sale: Revvity CAO Anita Gonzales sells 85 shares at $109.48 – a routine, plan‑based move amid steady growth and 8.4% YTD gain. Explore the details.

Harmony Biosciences CFO’s new share purchase shows insider confidence, hinting at upside for investors eyeing breakthrough neurologic therapies.